ホーム › トリプルネガティブ乳がん › バージニア
バージニアにおけるトリプルネガティブ乳がんの臨床試験
バージニア内の拠点で、トリプルネガティブ乳がんに関する28件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Virginia Oncology Associates (VOA) ( Site 8002), Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Mary Washington Hospital ( Site 0129), Fredericksburg
- Hematology Oncology Associates of Fredericksburg ( Site 9550), Fredericksburg
- Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020), Midlothian
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of Virginia, Charlottesville
- Inova Fairfax Hospital, Fairfax
- Bon Secours Cancer Institute at St. Francis, Midlothian
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Bon Secours St. Francis Medical Center, Midlothian
- Local Institution - 0301, Roanoke
- Shenandoah Oncology, P.C., Winchester
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
被験者募集中第2相
18歳以上 · 女性 · 2026/07/21更新 · NCT04348747A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403Study of XB010 in Subjects With Solid Tumors
- Inova Schar Cancer, Fairfax
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT06545331A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/18更新 · NCT07503808A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Virginia Oncology Associates, Norfolk
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/30更新 · NCT06926920A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- Next Oncology, Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2024/01/26更新 · NCT05746897ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。